Vanda Pharmaceuticals Inc. — Director's Dealing 2019

Apr 24, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2019-04-23

Reporting Person: Chrousos Phaedra (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-04-23	Stock Option (Right to Buy)	$17.31	A	35000	Acquired	2029-04-22	Common Stock (35000)	Direct

Footnotes

F1: The option vests with respect to 25% of the underlying shares when the Reporting Person completes 12 months of continuous service following the date of grant, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.